Effect of Hydroxyethyl Starch on Systemic Inflammatory Response Syndrome after Extracorporeal Circulation

LIU Hui-li,MIAO Qi,CAO Li-hua,LUO Ai-lun,HUANG Yu-guang
DOI: https://doi.org/10.3969/j.issn.1672-1403.2007.03.006
2007-01-01
Abstract:OBJECTIVE To investigate the safety of hydroxyethyl starch(HES) 130/0.4 in patients undergoing coronary artery bypass grafting(CABG),and to compare its efficacy on systemic inflammatory response syndrome(SIRS) after extracorporeal circulation(ECC) with Gelofusine.METHODS Twenty-four patients scheduled for elective CABG were randomized to receive either HES 130/0.4(group Ⅰ,n=12) or Gelofusine(group Ⅱ,n=11) as prime solution and volume replacement.Fluid therapy was given perioperatively and continued for 48 h postoperation.The incidence of SIRS,postoperative clinical parameters and blood biochemistry were recorded. The serum concentrations of C-reactive protein(CRP),interleukin(IL)-6,P-selection and intercellular adhesion molecule-1(ICAM-1) were measured after induction of anesthesia,at the end of ECC,as well as 2 hours,24 hours and 48 hours after the end of ECC for both groups.RESULTS Liver enzymes in group Ⅰ were significantly higher than that in group Ⅱ(P<0.05).There was no difference in the number of patients suffering from SIRS.Twenty-four and 48h after ECC,the CRP levels were increased in two groups,but the difference was statistically significant only at 48h between the two groups(P<0.05).Serum concentrations of ICAM-1 were significantly higher in two groups at 24 hours and 48h after the end of ECC.CONCLUSION HES 130/0.4 can be safely used in patients undergoing CABG,although caution should emphasized on its potential liver damage.Compared to Gelofusine,volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing CABG surgery,because of reducing endothelial activation and endothelial damage induced by HES 130/0.4.
What problem does this paper attempt to address?